Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the proper dose, effectiveness, and safety of using
Iodine-131 Anti-B1 Antibody for the treatment of patients with previously treated
non-Hodgkin's lymphoma (NHL) who have greater than 25% bone marrow involvement with lymphoma.